Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc.
Your view on NWBO
Overview
What the company does, where it operates, and who runs it.
About Northwest Biotherapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Linda F. Powers
- Headquarters
- 4800 Montgomery Lane, Bethesda, MD, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Linda F. Powers
- Headquarters
- 4800 Montgomery Lane, Bethesda, MD, US
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Northwest Biotherapeutics, Inc., and the rating behind it. NWBO last traded at $0.23; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Northwest Biotherapeutics, Inc.. Starting points for Northwest Biotherapeutics, Inc.: EPS -$0.02, beta -0.85 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Northwest Biotherapeutics, Inc.. Northwest Biotherapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Northwest Biotherapeutics, Inc.. Trailing twelve-month EPS for Northwest Biotherapeutics, Inc. stands at -$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Northwest Biotherapeutics, Inc.. Northwest Biotherapeutics, Inc. has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Northwest Biotherapeutics, Inc. valued side by side against its closest peers. Northwest Biotherapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Northwest Biotherapeutics, Inc., and how their positions are changing. At a $359.4M market value, institutional positions materially move Northwest Biotherapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Northwest Biotherapeutics, Inc. executives and directors. Shares of Northwest Biotherapeutics, Inc. have traded between $0.17 and $0.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Northwest Biotherapeutics, Inc.. Northwest Biotherapeutics, Inc. is a $359.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Northwest Biotherapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Northwest Biotherapeutics, Inc.. Coverage tracks Northwest Biotherapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.